Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790842 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
A Phase 1 study, sponsored by PrECOG.
- Terminated
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT00790842 is a Phase 1 study that was terminated before completion, run by PrECOG. The registered enrollment target is 63 participants.
The verdict
NCT00790842, a Phase 1 study, was terminated before completion, sponsored by PrECOG.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Anticoagulants
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-01-21 |
| Est. Completion | 2018-03-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790842
The ClinicalTrials.gov registry entry for NCT00790842 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT00790842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790842 about?
NCT00790842 is a clinical study titled "Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction". Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose ...
What is the current status of trial NCT00790842?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2009-01-21. Estimated completion is 2018-03-08.
What interventions are being tested in trial NCT00790842?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Anticoagulants (DRUG).
Who is sponsoring clinical trial NCT00790842?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.